Trimethyl(2-naphtho[2,1-g][1,3]benzodioxol-5-ylethyl)azanium

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 6,6a-仲卟啉
• 英文名称: Trimethyl(2-naphtho[2,1-g][1,3]benzodioxol-5-ylethyl)azanium
• 化学式: C20H22NO2+
• 分子量: 308.4
• InChiKey: SUXCFKVPIRPDAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Phenanthrene derivatives for use as medicaments
  申请人：Valentia Biopharma

  公开号：EP2742974A1

  公开（公告）日：2014-06-18

  Phenanthrene derivatives of formula I for use as medicaments. The present invention refers to phenanthrene derivatives for use as medicaments, mainly in the prevention and/or treatment of DM1, HDL2, SCA8, DM2, SCA3, FXTAS, FTD/ALS, and SCA31. In a preferred embodiment, phenanthrene derivatives of the invention are also used as antimyotonic agents.

  公式I的菲南三烯衍生物用作药物。本发明涉及用作药物的菲南三烯衍生物，主要用于预防和/或治疗DM1、HDL2、SCA8、DM2、SCA3、FXTAS、FTD/ALS和SCA31。在一个优选实施例中，本发明的菲南三烯衍生物也用作抗肌肉张力剂。
• PHENANTHRENE DERIVATIVES FOR USE AS MEDICAMENTS
  申请人：VALENTIA BIOPHARMA

  公开号：US20160194274A1

  公开（公告）日：2016-07-07

  The present invention refers to phenanthrene derivatives for use as medicaments, mainly in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spinocerebellar Ataxia Type 3, Fragile-X-Associated Tremor/Ataxia Syndrome, Frontotemporal Degeneration/Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia Type 31. In a preferred embodiment, phenanthrene derivatives of the invention are also used as antimyotonic agents. Therefore, this invention may be included either in the whole pharmaceutical or medical field.

  本发明涉及苯并并芘衍生物作为药物的用途，主要用于预防和/或治疗肌无力型1型、亨廷顿病类2型、脊髓小脑共济失调型8型、肌无力型2型、脊髓小脑共济失调型3型、脆性X相关震颤/共济失调综合征、额颞叶退行性/肌萎缩侧索硬化和脊髓小脑共济失调型31型。在一个首选实施例中，本发明的苯并并芘衍生物也用作抗肌无力剂。因此，本发明可包括在整个制药或医学领域中。
• [EN] PHENANTHRENE DERIVATIVES FOR USE AS MEDICAMENTS<br/>[FR] UTILISATION DE DÉRIVÉS DE PHÉNANTHRÈNE COMME MÉDICAMENTS
  申请人：VALENTIA BIOPHARMA

  公开号：WO2014091020A1

  公开（公告）日：2014-06-19

  The present invention refers to phenanthrene derivatives for use as medicaments, in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spinocerebellar Ataxia Type 3, Fragile-X- Associated Tremor/ Ataxia Syndrome, Frontotemporal Degeneration/Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia Type 31. In a preferred embodiment, phenanthrene derivatives of the invention are also used as antimyotonic agents. Therefore, this invention may be included either in the whole pharmaceutical or medical field.